Related Experiment Video
Updated: Feb 14, 2026

Home-Based Prescribed Pulmonary Exercise in Patients with Stable Chronic Obstructive Pulmonary Disease
Published on: August 24, 2019
Prevalence of Beta Blocker Prescribing for Hypertension
Brandon J Skory1, John Arko1, Laila Terkawi1
1College of Pharmacy, Northeast Ohio Medical University, Rootstown, OH, USA.
Insights
Beta blockers are frequently prescribed inappropriately for hypertension in the US. This study found over 93% of beta blocker prescriptions lacked compelling indications, especially in older adults.
Area of Science:
- Cardiology
- Pharmacology
- Public Health
Background:
- Beta blockers are not recommended as first-line treatment for hypertension (HTN) unless specific compelling indications exist.
- Despite guidelines, evidence suggests beta blockers are often inappropriately prescribed to US adults with HTN.
Purpose of the Study:
- To determine the rate of beta blocker prescribing for hypertension without concurrent use of other first-line antihypertensive agents.
- To identify factors associated with inappropriate beta blocker prescribing in hypertension management.
Main Methods:
- Analysis of National Ambulatory Medical Care Survey data from 2013-2018 (excluding 2017).
- Inclusion of office visits for adult patients receiving hypertension treatment.
- Study encompassed 5191 unweighted visits, representing 247 million nationally.
Main Results:
- Beta blockers were prescribed in 21.8% of analyzed visits.
- 93.6% of beta blocker prescriptions were deemed inappropriate based on guideline recommendations.
- Older age (≥65) and elevated blood pressure increased likelihood of beta blocker prescription.
Conclusions:
- Inappropriate beta blocker prescribing for hypertension without compelling indications is highly prevalent in US outpatient settings.
- Older adults and patients with elevated blood pressure are at higher risk for inappropriate prescribing.
- Provider education and clinical decision support are needed to improve hypertension management.
Abstract:
Background: Beta blockers are no longer recommended as first-line agents for hypertension (HTN) without compelling indications; however, evidence suggests that there is still frequent inappropriate prescribing of beta blockers to many US adults with HTN. Objective: To determine rate of prescribing of beta blockers for HTN without concurrent use of other first line antihypertensive agents. Methods: To analyze the validity of these claims, we utilized National Ambulatory Medical Care Survey data from 2013 to 2018 (excluding 2017). This data represented office visits related to adults receiving treatment for HTN. The data in the study encompasses 5191 unweighted visits representing 247 million visits nationally. Results: The data from these visits showed the prevalence of beta blocker prescribing to be 21.8% with 93.6% of beta blocker prescriptions considered inappropriate based on current guideline recommendations. This determination was made based on whether the patient had all first-line HTN treatment options prescribed prior to receiving beta blockade. Factors such as older age (≥65 years; odds ratio [OR] = 1.48, 95% CI = 1.11-1.97) and elevated blood pressure at the visit (OR = 1.43, 95% CI = 1.06-1.92) were associated with an increased likelihood of beta blocker prescribing, while depression (OR = 0.42, 95% CI = 0.24-0.73) and diabetes (OR = 0.70, 95% CI = 0.55-0.90) were associated with decreased likelihood. Conclusion: Inappropriate beta blocker prescribing for HTN without compelling indications remains highly prevalent in US outpatient practice. Older adults and patients with elevated blood pressure are particularly at risk. Targeted provider education and clinical decision support interventions are warranted to improve hypertension management.
Related Concept Videos
Prevalence and Incidence
Prevalence indicates the proportion of individuals in a population who have a specific disease or health...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Hypertension I: Introduction
Hypertension II: Pathophysiology
Hypertension V: Nursing Management
Depolarizing Blockers: Pharmocokinetics

